MOLN trades 242.1% below Wall Street's consensus target of $13.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MOLN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Molecular Partners AG (MOLN) has a Wall Street consensus price target of $13.00, based on estimates from 4 covering analysts. With the stock currently trading at $3.80, this represents a potential upside of +242.1%. The company has a market capitalization of $143M.
Analyst price targets range from a low of $13.00 to a high of $13.00, representing a 0% spread in expectations. The median target of $13.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 1 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, MOLN trades at a trailing P/E of -1.9x. Analysts expect EPS to grow +14.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
XNCRXencor, Inc. | $1.1B | $15.05 | $35.30 | +134.6% | Buy | — | 27 |
MRUSMerus N.V. | $6.8B | $90.00 | $88.69 | -1.5% | Hold | — | 22 |
IMVTImmunovant, Inc. | $8.0B | $38.85 | $45.00 | +15.8% | Buy | — | 23 |
ALKSAlkermes plc | $9.2B | $55.08 | $49.50 | -10.1% | Buy | — | 29 |
RCUSArcus Biosciences, Inc. | $3.1B | $31.00 | $31.00 | +0.0% | Buy | — | 18 |
ABBVAbbVie Inc. | $444.4B | $251.52 | $258.00 | +2.6% | Buy | 17.7x | 41 |
REGNRegeneron Pharmaceuticals, Inc. | $65.8B | $632.90 | $836.00 | +32.1% | Buy | 13.6x | 48 |
HALOHalozyme Therapeutics, Inc. | $8.9B | $74.96 | $88.25 | +17.7% | Buy | 9.2x | 27 |
ADMAADMA Biologics, Inc. | $2.0B | $8.75 | $21.00 | +140.0% | Buy | 10.6x | 10 |
AGENAgenus Inc. | $126M | $3.03 | $7.33 | +141.9% | Buy | 3.9x | 11 |
Quick answers to the most common questions about buying MOLN stock.
The consensus Wall Street price target for MOLN is $13, representing 242.1% upside from the current price of $3.8. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MOLN has a consensus rating of "Hold" based on 4 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $13 implies 242.1% upside from current levels.
MOLN's current price is $3.8 with a consensus target of $13 (242.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $13 for MOLN, while the most conservative target is $13. The consensus of $13 represents the median expectation. These targets typically reflect 12-month expectations.
MOLN is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MOLN stock forecast based on 4 Wall Street analysts shows a consensus price target of $13, with estimates ranging from $13 (bear case) to $13 (bull case). The median consensus rating is "Hold".
Wall Street analysts are very optimistic on MOLN, with a "Hold" consensus rating and $13 price target (242.1% upside). 1 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MOLN analyst price targets range from $13 to $13, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $13 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.